Background Expression of oncostatin M receptor beta (OSMRβ) has been reported in human cancers, however its role in esophageal squamous cell carcinoma (ESCC) remains unknown. Using differential display, earlier we reported the identification of an alternatively spliced variant of OSMRβ in ESCC. Here in we characterized this novel variant encoding a soluble form of this receptor (sOSMRβ) and determined its clinical significance and correlation with the expression of oncostatin (OSM) and leukemia inhibitory factor receptor beta (LIFR β) in ESCC. Materials and Methods In silico analysis was carried out to characterize the differentially expressed transcript of OSMRβ and its expression was determined in ESCCs and matched normal esophageal tissues using semiquantitative RT-PCR. The expressions of both truncated and full length OSMRβ proteins were analyzed in ESCC tissues and patients' sera using western blotting and immunoprecipita- tion. By immunoprecipitation we have also shown direct interaction between sOSMRB and OSM. We also explored the relationship between expression of OSM and its receptors, OSMRβ and LIFRβ, in primary human ESCCs and normal epithelia using immunohistochemistry. Results Overexpression of alternatively spliced OSMR β transcript was detected by RT-PCR in 9 of 11 ESCCs. Analysis of the soluble receptor revealed absence of sOSMRβ protein in esophageal tissues, however, immunoprecipitation and western blot analysis showed its presence in sera of ESCC patients further confirming expression of the alternatively spliced OSMR β in ESCC patients. Immunohistochemical analysis in tissue microarray (TMA) format showed expression of OSMR β, LIFR and OSM in 11/50 (23%), 47/50 (94%) and 47/50 (94%) ESCCs, respectively. Strong correlation was observed between cytoplasmic expression of LIFRβ and OSM in tumor cells (p=0.000, O.R =50, 95%CI=8-31.9), and nuclear expression of LIFRβ and OSM (p=0.039 OR= 3.1, 95% CI=1.1-8.2), suggesting that LIFRβ serves as the major receptor in ESCCs. Conclusion An alternatively spliced variant of OSMR transcribing a soluble form of this receptor has been characterized in ESCC. We speculate that the truncated OSMR characterized here in may act as a neutralizing receptor for OSM. Our immunohistochemical study showed that OSMRβ and its pathway is not activated in ESCCs.
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Introduction
Esophageal cancer (EC) ranks as the 6th most common cancer among males and 9th most common cancer among females globally [1] . Despite advances in multimodality therapy, due to insidious symptomatology, late stage of diagnosis and poor efficacy of treatment, the prognosis for patients with esophageal squamous cell carcinoma (ESCC) still remains poor, with an average 5-year survival of <10% globally [2] and 12% in India [3] . There is an urgent need to identify molecular alterations associated with early stages of development of ESCC to enable early detection, better management of the disease and improvement of quality of life. Therefore several techniques are being utilized to identify new molecular targets [4] . In search of novel molecular markers for esophageal cancer recently we carried out differential display reverse transcription polymerase chain reaction [DDRT-PCR] , during this study we isolated a cDNA fragment, showing homology to a clone similar to Oncostatin M Receptor β (OSMRβ) [5] .
OSMR is a receptor of Oncostatin M (OSM) which is an interleukin-6 (IL-6)-type cytokine. Human OSM forms two types of heterodimeric signaling complexes; gp130/leukemia inhibitory factor receptor (LIFR) (type I OSM receptor complex) [6] and gp130/OSMR (type II OSM receptor complex) [7] . gp130/LIFR can be activated by LIF or OSM, but gp130/OSMR is activated by OSM only. The type II receptor complex activates OSM-specific signaling pathways via the JNK/SAPK and Stat1/Stat5 pathways, whereas both type I and type II complexes activate Stat3 and Erk as common signaling pathways in breast cancer cells [8] . There are reports which suggest that IL-6-type cytokine receptors can also be present in souble form and these soluble cytokine receptors are involved in the regulation of a number of physiological and pathological conditions. They can behave either as agonists or antagonists of cytokine signaling depending on the particular family of cytokines. Soluble cytokine receptors can be generated by different mechanisms-alternative splicing of RNA transcripts, or cleavage of a glycosylphosphatidylinositol anchor [9] . The soluble counterparts such as soluble IL-6 or ciliary neurotrophic factor (CNTF) receptors are able to potentiate the functional responses to their respective ligands [10, 11] . In contrast, soluble receptors, such as soluble gp130, neutralize the response to IL-6, IL-11, or CNTF [12] . The interaction of OSM with its specific type II receptor mediates the unique functions of OSM that cannot be mimicked by LIF or other IL-6 family members.
Human OSM was originally identified by its capacity to inhibit melanoma proliferation in vitro [13, 14] . However, other reports described its tumor growth promoting activities in prostate cancer, Kaposi's sarcoma and breast cancer [15] [16] [17] . There are conflicting reports on the role of OSM in cancer development varying according to the type of cancer. It would be interesting to investigate the relationship of OSM with it's receptors OSMRβ and LIFRβ in the same tumor type to support it's functions.
Therefore, we delineated the expression and relationship of OSM protein and its receptors OSMR β and LIFR β in ESCCs and normal esophageal epithelia using immunohistochemistry (IHC) in tissue microarray (TMA) format and confirmed the findings independently by western blot analysis. Previously we also found over-expression of a novel truncated OSMR β transcript in ESCCs compared to normal esophageal tissues. During this study we also characterized this differentially expressed alternatively spliced variant of OSMRβ.
Materials and methods

Tissue specimens
The Human Ethics Committee of All India Institute of Medical Sciences, New Delhi, India, approved this study.
Biopsy specimens or surgically resected tissues from esophageal carcinomas, distant dysplastic lesions and distant morphologically normal esophageal tissues were obtained from Department of Gastrointestinal Surgery, and banked at All India Institute of Medical Sciences, New Delhi, with prior informed written consent of the patients. Specimens of normal esophageal tissues were obtained from cancer patients from an area distant to the site of the esophageal lesions. Paired cancer and normal esophageal tissue samples from the same patient were used for RT-PCR and immunoblotting study, however, the normal tissues used in TMA are independent samples and do not match to any tumor present in the array. Esophageal cancer samples with at least 70% cellularity were identified using hematoxylin-stained frozen sections, and 2-mm 3 samples were obtained for RNA and protein isolation. The sections were then examined by the study pathologist (S.D.G) to confirm the histopathological diagnosis of esophageal squamous carcinoma or normal esophageal mucosa.
Cells and reagents
The human esophageal squamous cell carcinoma cell line TE13 used in this study was cultured in RPMI 1640 medium supplemented with 10% fetal calf serum. Antibodies raised against OSMRβ (sc-9992), this antibody recognizes both the full length and truncated form of OSMRβ, Oncostatin M (OSM) (sc-129), Leukemia Inhibitory Factor receptor (LIFR) (sc-659) and actin (sc-47778) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Esophageal cancer tissue microarrays were procured from IMGENIX India Pvt. Ltd. (Bhubhaneshwar, India,).
Sera samples
This study commenced after approval by the Human Ethics Committee of All India Institute of Medical Sciences (AIIMS), New Delhi, India and obtaining patients' consent prior to sample collection. Blood samples were collected from ESCC patients from Departments of Gastroenterology and Gastrointestinal Surgery, AIIMS. Blood samples from normal healthy volunteers, with no prior history of any major ailment and with no evidence of disease were used as controls for immunoblotting. The sera were separated and stored in aliquots at −80 o C till use.
In silico analysis
In silico analysis of truncated OSMRβ transcript was carried out using software for topology (www.expasy. org/tools/topology prediction) and for hydrophobicity (http://www.expasy.org/tools/protscale.html).
RNA isolation and reverse transcription-PCR analyses
RNA isolation and semiquantitative RT-PCR were performed as previously described by us (5) . Briefly, cDNAwas prepared using 2μg of total RNA and Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA) with oligo dT as the primer. PCR amplification was carried out with full length OSMRβ specific primers: (Forward) 5′ GTG TGG GTG CTT CTC CTG CTT CTG TA and 3′ (Reverse) 5′TCT GTG CTA ATG ACT GTG CTT GTG GT 3′ at 95°C for 2.5 min, 95°C for 60 s, annealing temperature of 56°C for 1 min for 35 cycles, extension at 72°C for 45 s and final extension at 72°C for 5 min. In case of truncated (alternatively spliced transcript) OSMRβ using specific primers: 5′ TGG AAT GTG CCA CAC ACT TTG 3′ (Forward) and 5′ GGT GGG CTG TGA CAA CTC TAG 3′ (Reverse) we used above mentioned conditions with annealing temperature of 54°C for 1 min for 35 cycles β actin was reverse transcribed for all the samples to check for the quality and quantity of the initial RNA used. The sequences of β actin primer used are 5′AAATCTGGCAC CACACCTTC 3′ (Forward) and 5′AGC ACT GTG TTG GCG TACAG3′(Reverse), which give product size of 646 bp. The PCR amplified products were electrophoresed on 1.2% agarose gels and bands were visualized by ethidium bromide staining. The PCR reactions were carried out in triplicate for both normals and tumor samples. For quantitation, we compared the levels of OSMR β transcript between tumor and distant normal samples of the same patient. For quantification of relative transcript levels, gel pictures were scanned and analyzed using ImageJ 1.32j software (NIH, Bethesda, MD).
Western blot analysis
Western blotting was performed as described by us previously [18] . Briefly, total cellular proteins (50 μg protein/lane) from TE13 cells, esophageal normal and cancer tissues were resolved on 8%-10% SDSpolyacrylamide gels, transferred to PVDF membranes and immunolabelled with anti-OSMRβ (0.2 μg/μl) anti-LIFRβ (0.2 μg/μl), and anti-OSM (0.2 μg/μl) in 1% non-fat milk overnight at 4°C. Protein abundance of actin served as a control for protein loading, and was determined with mouse monoclonal anti-actin antibody. Membranes were incubated with respective HRP-conjugated secondary antibodies. HRP-conjugated immunolabelled proteins were detected by enhanced chemiluminescence method (ECL, Santa Cruz Biotechnology, CA).
Immunoprecipitation and co-immunoprecipitation
To detect truncated form of OSMRβ, immunobloting was carried out after immunoprecipitation of OSMRβ protein from serum using standard protocol. Briefly, serum was diluted in PBS (1:1) and centrifuged for 30 min to remove cell debris. Thereafter, sera were pre-cleared by adding protein A-Sepharose (GE Healthcare Biosciences, Sweden) followed by incubation with OSMRβ monoclonal antibody (5 μg) over-night on a rocker at 4°C. Immune complexes were pulled down by incubating with Protein A-Sepharose for 4 hrs at 4°C followed by washing with ice-cold lysis buffer 4-5 times, to eliminate non-specific interactions. Protein A-Sepharose bound immune-complexes were then resuspended in Laemelli sample buffer, boiled for 5 min and analyzed by western blotting as described above. In negative control, the primary antibody was replaced by isotype specific IgG. Co-immunoprecipitation was carried out in order to confirm interaction between soluble OSMRβ and OSM. For this immunoprecipation was carried out as described above in sera using OSM antibody followed by immunoblotting with OSMRβ antibody.
Immunohistochemistry and TMA
The expressions of OSMRβ, OSM and LIFRβ proteins were analyzed on TMA with formalin fixed paraffin-embeded human esophageal normal and cancer tissues.
Immunohistochemical staining was performed using DAKO LSAB + kit (DAKO, Carpinteria, CA) and diaminobenzidine as chromagen. Dewaxed and rehydrated 4 μm thick sections of the TMA were incubated with primary antibody anti-OSMRβ (0.2 μg/μl), anti-LIFRβ (0.2 μg/μl) and anti-OSM (0.2 μg/μl) for 16 h at 4°C at after microwave citric acid epitope retrieval for 20 min. Slides were lightly counterstained with hematoxylin and processed for permanent viewing and coverslipped. Appropriate positive and negative controls were included in the immunohistochemistry experiments.
Evaluation of immunohistochemical staining
The immunopositive staining was evaluated in five areas of the slide sections for correlation and confirmation of the tissue analysis. Sections were scored as positive if tumor cells showed immunopositivity in the epithelial cells (cytoplasm and nucleus) and/or stroma when judged independently by two scorers who were blinded to the clinical outcome, i.e., the slides were coded and the pathologists did not have prior knowledge of the local tumor burden, lymphonodular spread, and grading of the tissue samples, while scoring the immunoreactivity. First, a quantitative score was given by estimating the percentage of immunopositive-stained cells: 0<10% cells, 1=10-30% cells, 2=30-50% cells, 3=50-70% cells and 4=>70% cells. Second, the intensity of staining was scored by evaluating the average staining intensity of the positive cells (0, none; 1, weak; 2, intermediate; and 3, strong). Finally, a total score (ranging from 0 to 7) was obtained by adding the quantitative score and the intensity score for each section. The sections were considered positive for OSM and LIFR staining if the total score was ≥3 and for OSMR β staining if the total score was ≥4.
Statistical analysis
Statistical analyses of the data were performed using SPSS software, version 9.01 (SPSS, Chicago, IL). The correlation between the protein expression and clinicopathological parameters of esophageal cancer patients were examined by Chi-square test or Fischer's exact test. Two sided p values were calculated and p≤0.05 was considered to be significant.
Results
Identification of a splice variant of OSMRβ
In search for novel molecular markers for esophageal cancer using differential display reverse transcription polymerase chain reaction (DDRT-PCR), we isolated a cDNA fragment, showing homology to a clone similar to Oncostatin M Receptor β (OSMRβ) (5). This clone BC010943 was 1620 bp long and on further sequence analysis was found to encode a truncated form of OSMRβ of 342 amino acids diverging from the membrane form of OSMR by 12 amino acids encoded at the end of exon 7 (Fig. 1) . The truncated receptor sequence included a Nterminal potential hydrophobic signal peptide (exons 1 and 2), a half Cytokine binding Domain (CBD) containing a WSXWS motif (exons 3 and 4) followed by an Ig-like domain (exon 5), and then a portion of half CBD presenting four conserved cysteine residues in fixed position (exon 6).
Expression of full length and truncated OSMRβ mRNA in esophageal tissues and cell line
RT-PCR analysis of the full length and truncated OSMRβ mRNA expression was carried out in 12 surgically resected ESCCs and distant normal esophageal tissues. Figure 2a shows the annealing sites of full length and truncated primer site showing their specificity for the two forms of receptor. Eleven of 12 ESCCs showed expression of both the full length (235 bp) and truncated (703 bp) OSMRβ transcripts. Nine of 11 ESCCs showed overexpression of the truncated transcripts as compared to the normal tissue. However, 7 of 11 ESCCs showed overexpression of the full length transcript with respect to the normal tissue (Fig. 2b) of any of these transcripts. The surgically resected ESCC tissue specimens comprise of heterogeneous population of different cell types, therefore, to confirm the expression of OSMRβ mRNA in cancer cells, we analyzed its expression in an esophageal cancer cell line (TE13). Both the OSMRβ transcripts were observed in TE13 cells suggesting that this receptor is expressed in tumor cells (Fig. 2b) . Bar diagram in Fig. 2c shows the expression levels of OSMRβ transcripts in tumors relative to adjacent normals in 12 ESCCs patient. Table 1 shows the histopathological parameters of ESCCs patients analyzed in this study.
Western blot and immunoprecipitation analysis
Western blot analysis was carried out in surgically resected ESCCs, distant normal esophageal tissues and esophageal cancer cell line. Western blot analysis showed specific bands of molecular weights 25, 150 and 110 kDa respectively for OSM, LIFRβ and OSMRβ (full length protein) in ttt tct ggg gaa aag aaa ctt tgt aca cac aaa aac tgg tgt aat tgg caa ata act caa gac tca caa gaa acc tat aac ttc aca ctc ata gct gaa aat tac tta agg aag aga ag t gtc aat atc ctt ttt aac ctg act cat cga ggt gag act aga gtt gtc aca gcc cac cgt ggc cac taa cgtgtctttgtttcacagactgtgtgatcaagtaaatgtgctgtagatctttgcctcattcacagcggaggtgagagttagaatttata cctattgttcatgccacgtttctcctcatggatgcacgcatcccctattatttgtttcttttaataatgtcacgagcaccaatgagcttact acccaacttcaaaactaggactctaacaataacttctgtcatatctcatcctgtaacgcccccaccttcgctccttccgccaagataa ttatcactttaaattgtgtgcgtgtgtattctcatttcttatgtgatggtaaaaatgcctttattttgtttggttttatgcatagaaaggacat caagctgtatgtaataattcagtaattatgtttatataatattaaattgctaatatttgccctcaaaaaaaaaaaaaaaaaaaaaaaaaa aaaaa d Fig. 1 (continued) ESCCs (Fig. 3a) and also showed their overexpression as compared to the normal tissue lysate. In contrast the product of alternatively spliced transcript of OSMRβ (truncated OSMRβ) was not detected in esophageal tissues. Since the truncated OSMRβ encoded for the extracellular domain of full length OSMRβ we hypothesized it to be secreted out by the cells as the soluble form of OSMRβ. To test this hypothesis we carried out immunoprecipitation of OSMRβ in sera of six ESCC patients and three normal individuals. Western blotting after immunoprecipitation from ESCC sera samples revealed a band around 40 kDa which corresponded to the truncated OSMRβ protein (Fig. 3b) .
Truncated OSMR primers
Co-immunoprecipitation
Co-immunoprecipitation was carried out to confirm interaction between soluble OSMRβ and OSM. For this, same ESCCs patient sera were used as for detecting truncated OSMRβ. We observed 40 kDa band of soluble OSMRβ in sera after immunoprecipation using OSM antibody followed by immunobltting with OSMRβ antibody. These results confirm our hypothesis, that soluble OSMRβ interact with OSM and neutralizes it (Fig. 3c ).
Expression of OSMRβ, oncostatin M (OSM) and leukemia inhibitory factor receptor (LIFR) proteins in human esophageal tissues
We determined the expression of OSM and its receptors, LIFRβ and OSMRβ in a set of 50 primary ESCCs and 10 normal esophageal epithelia using tissue microarray by immunohistochemistry. The results of the immunohistochemical analyses of all the three proteins in ESCCs and non-malignant mucosa, and their relationship with clinicopathological parameters, are summarized in Table 2 ). The normal esophageal tissues showed weak OSMRβ immunoreactivity localized exclusively in the stromal cells (Fig. 4a) . In ESCCs, OSMRβ immunostaining was distributed in the cytoplasm of epithelial and stromal cells. Ten of 50 (20%) cases showed immunostaining in stromal components, while 11/50 (22%) ESCCs showed cytoplasmic staining of OSMRβ in the tumor cells; 1 ESCC showed nuclear staining in addition to the cytoplasmic staining (Fig. 4b, c) . LIFRβ was weakly detected in the basal cells of the normal epithelium (Fig. 4d) . No detectable expression or weak immunoreactivity of LIFRβ was observed in stromal cells of the normal esophageal tissues. In ESCCs, 47/50 (94%) cases showed cytoplasmic staining with a higher labeling intensity than that seen in the normal esophageal tissues. Fourteen of 50 (28%) cases showed nuclear staining in addition to cytoplasmic staining. Thirty-nine of 50 (78%) cases showed stromal staining of LIFRβ in ESCCs (Fig. 4e, f) .
In normal esophageal tissues weak OSM immunostaining was observed in both stromal cells and cytoplasm of epithelial cells (Fig. 4g) . In ESCCs, 47/50 (94%) cases showed cytoplasmic staining, 31/50 (62%) cases showed stromal staining while 15/50 (30%) showed nuclear staining in addition to the cytoplasmic staining. Strong OSM immunoreaction was observed in both epithelial cells and stroma of most ESCCs (Fig. 4h, i) Two of 10 normal esophageal tissue sections were positive for all the three proteins. In ESCCs 9 (18%) cases were positive for OSM, LIFRβ, and OSMRβ. Pairwise comparison of the immunoexpression of OSM with LIFRβ and OSMRβ was also carried out. OSM was found to be co-expressed along with LIFRβ in epithelial cells of 47/50 (94%) ESCCs. Strong correlation was found between cytoplasmic expression of LIFRβ and OSM in tumor cells (p=0.000, OR=50, 95%CI=8-31.9), and LIFRβ and OSM nuclear expression (p=0.039 OR=3.1, 95% CI=1.1-8.2). These results suggest that LIFRβ may serve as the major receptor in a potential OSM based autocrine (or paracrine) network, and that such a network occurs in most ESCCs.
Discussion
The role of cytokines and growth factors in tumor development and progression has been the focus of recent attention. Our work assumes importance as we report the expression and characterization of an alternatively spliced form of OSM receptor leading to generation of soluble form of receptor. We also studied protein expression of OSM and its receptors in ESCCs by Immunohistochemistry.
Soluble type I cytokine receptors have been shown to be generated by alternate mRNA splicing or proteolytic shedding of receptor ectodomains or cleavage of glycosylphosphatidylinositol-anchored receptor by phosphatidylinositol-specific phospholipase C as reported for CNTFR α-chain [9] . Shedding of the external IL-6R Parameters Total Cases (N) C S N overall staining C S N overall staining C S N overall staining (+) (+) (+) (+) (+) (+) (+) (+) (+) (+) (+) (+) n n n n n n n n n n n n [19] [20] [21] . Two large size signaling receptors belonging to the IL-6 family, gp130 and LIFR have also been described as soluble products [11, 22] . In these cases the soluble receptors have been identified as splice variants of membrane forms.
In the present investigation, we have highlighted the existence of a soluble OSMR generated by alternative splicing and diverging from the membrane form of OSMR by 12 amino acids enclosed at the end of exon 7. The mRNA expression analysis of both the OSMR transcripts, full length and soluble OSMR (truncated) transcripts, carried out in this study revealed that both the membrane bound and soluble forms of OSMR are expressed in ESCCs. The in silico analysis of the alternatively spliced OSMR mRNA revealed the lack of transmembrane and cytoplasmic domains suggesting the secretion of this form of receptor as soluble receptor. The presence of truncated OSMR protein in sera of ESCC patients confirmed by western blot analysis further strengthened this hypothesis. We also carried out co-immunoprecipitation to confirm the interaction between soluble OSMRβ and OSM. We have observed 40 kDa band of soluble OSMRβ in sera after immunoprecipation in patient sera using OSM antibody followed by co-immunoprecipitation with OSMRβ antibody, demonstrating that soluble OSMR binds with OSM thus behaving as a neutralizing receptor for OSM in ESCCs.
Soluble cytokine receptors are involved in the regulation of a number of physiological and pathological conditions. They can behave either as agonists or antagonists of cytokine signaling depending on the particular family of cytokines. The binding of soluble IL-6R-IL-6 complex to membrane gp130 confers an IL-6 signaling capability named "trans-signaling" [23] . This phenomenon is also reported for IL-11 or CNTF [19, 24] . In contrast, soluble gp130 (sgp130) or soluble LIFR (s LIFR) abrogate the signaling mediated by the membrane form of receptors in response to the IL-6 family members [21, 22] . Considering lack of cytoplasmic and transmembrane domains in soluble OSMR analyzed in this study, it might be possible that soluble OSMR may behave as a neutralizing receptor of OSM in ESCCs. A similar phenomenon has already been described for Fas ligand. In this case, lung and colon tumor cells inhibited Fas ligand-induced apoptosis by overproducing a decoy receptor [23] . Interestingly, while our study was in progress, Diveu et al., reported another alternatively spliced form (spliced in intron 8) of OSM receptor leading to the generation of a soluble form of receptor (sOSMR) [24] . Using ELISA, this group detected high levels of soluble OSMR in glioblastoma and multiple myeloma cells and shown truncated OSMR, trap and neutralize OSM and thus behave as neutralizing receptor for OSM [25] . Our co-immunoprecipitaion result also supports that soluble OSMR binds with OSM and thus behaves as neutralizing receptor for OSM in ESCCs also in an analogous manner as shown in glioblastoma and multiple myeloma.
Recently, while our manuscript was under preparation, Chen et al., reported that expression of short-form of oncostatin M receptor in lung adenocarcinomas may act as a decoy receptor of OSM and is correlated with the disease progression and adverse prognosis in patients with this disease [26] . It is likely that sOSMR is binding with OSM and thereby limits the amount of OSM available for the membranous form of OSMRβ. Under these conditions, the expression of OSMRβ might not reflect the high expression of OSM because of the binding of OSM with sOSMR.
Although the expression of IL-6, IL-6 receptor alpha and gp130 have been reported to contribute to the progression of esophageal cancers in autocrine and paracrine manner [27] , little is known about the expression of OSM and its receptors in ESCCs. Thus, we further explored the expression of OSM and its receptors, OSMRβ and LIFRβ, in primary human ESCCs. OSM has been identified as a suppressor of tumor cell growth in a variety of cancers including melanoma [14] , ovarian [28] , glioblastoma carcinomas [29] . OSM has also been shown to stimulate the growth of the DU-145 human prostrate cancer cells and mediates the activation of STAT3 in this cell line [15] . OSM also can serve as an autocrine growth factor for Kaposi's sarcoma [16] . A recent report on breast cancer suggested that the development of breast tumors increases the expression of OSM, LIF, OSMRβ and LIFRβ, and this association was positively associated with tumor malignancy [17] . Thus, taken together, these findings suggest that expression and the biological action of oncostatin M may depend on cell type and context. Immunohistochemical analysis in the present study revealed expression of OSMRβ, LIFRβ and OSM in 11/50 (23%), 47/50 (94%) and 47/50(94%) ESCCs, respectively. From these results it is evident that OSMRβ and its pathway are not activated in ESCCs; whether LIFRβ pathway is the functional and active pathway in ESCC remains to be determined. LIFRβ can be stimulated by both OSM and LIF. LIF promoted cell proliferation in tumor cell lines, such as skin [30] , medulloblastoma [31] , breast, kidney, and prostate [32] . Wang et al., [33] showed that LIF together with LIFR appear to form a more stable complex with gp130 than OSM with gp130 and OSMRβ and co-activation of LIFR and OSMR resulted in a predominant LIF like resoponse. Moreover signaling by IL-6 cytokines is not identical and a hierarchical order of cytokine receptor action exists in which LIFR ranks as dominant member. The dominance of LIFRβ pathway over OSMRβ in ESCC needs to be assessed.
Thus analyzing the results of soluble OSMRβ expression in ESCCs and immunohistochemical analysis of OSM and its receptors we conclude that soluble OSMR may behave as a neutralizing receptor of OSM in ESCCs. The soluble OSMR levels were higher in ESCCs underscoring its importance in pathogenesis of the disease, especially when the expression of full length OSMRβ is low. Although it needs to be experimentally proven, however, it is likely that soluble OSMRβ could activate the downstream signaling pathways when full length OSMRβ is present at lower levels or is absent which can contribute towards importance of these pathways in ESCC development. The expression analysis of LIF in ESCCs is warranted to determine the contribution of LIFR mediated pathway to the progression of ESCC cells.
